Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.
about
Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer.Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a GruppPlerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation.Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum.Newly established stem cell transplant program: 100 days follow-up of patients and its comparison with published Indian literature.Impact of lenalidomide-based induction therapy on the mobilization of CD34(+) cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study.A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.Apheresis research-more abstracts should be published as full manuscripts to provide more evidence for clinical practice guidelines.Impact of T cells on hematopoietic stem and progenitor cell function: Good guys or bad guys?Mobilization of hematopoietic progenitor cells for autologous transportation: consensus recommendations.Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.Dynamic cellular phynotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced by SDF1α versus synthetic agents.UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach.Recombinant human thrombopoietin improves the efficacy of intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor in mobilizing peripheral blood stem cells in patients with multiple myeloma: A cohort study.Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.Impact of plerixafor (mozobil) on hospital efficiency: A single center experience.The evolution of stem-cell transplantation in multiple myeloma.Role of αβ T Cell Depletion in Prevention of Graft versus Host Disease.Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.
P2860
Q34886445-866FBD5F-3F49-4BDC-8EC7-E695C2B62D4DQ35588325-D7934323-C7EC-4409-850D-3507AE8388E3Q36072365-91691F09-7DA2-4ADD-ADC0-3EF44A9B6124Q36428104-AFF3E53B-F3F9-47D3-8EA1-17A7B5075338Q37136301-147D3ECF-8A79-4CA7-99A9-159C5B8FEC8CQ37265107-1F1BFECB-0266-4B8E-A899-43D5ED407AE0Q38691698-9A949B16-40FC-44ED-996A-765D789FE84DQ38771752-82A55856-37A4-41A7-99B8-E0B05903A8F0Q38797546-A57DD94A-477E-4455-AABF-2733D71B7AB8Q38880504-333FA681-0D06-4547-AA3A-75D78C30E7ABQ39002528-413A3CEA-D03C-4F1E-9042-4BB2CB0150E3Q39176779-2B570D9D-88A6-476F-8FD5-6950C485483AQ40407349-F87DCE21-E657-4532-9A50-FBC4319C9238Q41694417-A18EB08A-C8C8-4747-B1F2-D7D7A2707109Q48138880-45CFCF0C-0745-4182-A5D2-4909BDC2739BQ48251584-0557131D-327E-4680-BCD3-B5E920D66FC3Q48281446-32471A1B-418C-40A6-8EE8-5C677DB1A9F2Q49487144-B5D8B48A-E38D-42D1-9A8A-8E93AB6287EDQ49852695-A2F37B67-D45D-41C5-9343-AEEBB180C870Q50690379-8B3EAAFE-746F-4B3E-ABAE-0E4E322B854CQ52715329-75050C11-0A70-4C51-BE49-9F0FDE0AC7A7Q52763837-29F517B8-A32E-4705-857C-C87B0210D960Q53130499-0D83C580-991C-4C23-9553-844A581B1504
P2860
Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Peripheral blood progenitor ce ...... od and Marrow Transplantation.
@en
type
label
Peripheral blood progenitor ce ...... od and Marrow Transplantation.
@en
prefLabel
Peripheral blood progenitor ce ...... od and Marrow Transplantation.
@en
P2093
P1476
Peripheral blood progenitor ce ...... od and Marrow Transplantation.
@en
P2093
Bipin N Savani
Corey S Cutler
Ed Copelan
Helen Leather
Hien K Duong
John R Wingard
Luciano J Costa
Mark R Litzow
Miguel-Angel Perales
Mohamad Mohty
P304
P356
10.1016/J.BBMT.2014.05.003
P577
2014-05-09T00:00:00Z